Tens of thousands of people will be recruited into Alzheimer’s trials after a landmark drug was rejected for use on the NHS.

When I eventually got a bed it was usually in a ward full of elderly patients with various stages of Alzheimer’s. Each visit was a repeat ... private care homes will not be well pleased - but the NHS ...

The drug is a new treatment for Alzheimer's disease. However, the National Institute for Health and Care Excellence (NICE) has not recommended that donanemab is approved for use on the NHS. The ...

The UK's drug regulator granted approval for Kisunla, an Alzheimer's medication, while an independent assessment body rejected its NHS funding on grounds of cost. The approval marks the second ...

Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

Eli Lilly’s Alzheimer’s disease offering Kinsunla is poised to face a tough road ahead in the U.K. | Lilly's Alzheimer ...

A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like ...

The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being ...

A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...

England's drug-cost regulator rejcted Eli Lilly's Alzheimer's drug for use in the country's public health system, marking the second time a treatment for the disease has been deemed too costly.

The most effective drug for Alzheimer’s has been blocked for use on the NHS. Regulators have declared the new treatment for ...